Primary Tumor Location As a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients.

Wen-Zhuo He,Fang-Xin Liao,Chang Jiang,Peng-Fei Kong,Chen-Xi Yin,Qiong Yang,Hui-Juan Qiu,Bei Zhang,Liang-Ping Xia
DOI: https://doi.org/10.7150/jca.16804
IF: 3.9
2017-01-01
Journal of Cancer
Abstract:Background: Published papers reported contradictory results about the correlation between bevacizumab effectiveness and primary tumor location of metastatic colorectal cancer (mCRC). Methods: 740 mCRC patients treated with chemotherapy (CT group) and 244 patients treated with bevacizumab plus chemotherapy as first-line setting (CT + B group) were included. Propensity score analyses were used for patients' stratification and matching. Kaplan-Meier curves with log-rank tests were used to detect different overall survival (OS). Results: Patients in CT + B group had similar OS comparing with CT group only when the primary tumor located at right-side colon (20.2 for CT + B versus 19.7 months for CT group, p = 0.269). For left-side colon and rectal cancer patients, significantly longer OS were observed in CT + B than CT group. Conclusion: Our data suggested only patients with left-side colon or rectal cancer could get survival benefit from the addition of bevacizumab to first-line chemotherapy.
What problem does this paper attempt to address?